InsiderTrades

Form 4 for DRMA Dermata Therapeutics, Inc.

Accepted 2025-01-23 00:00:00 ET · period of report 2025-01-21 · accession 0001654954-25-000690 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DI 2025-01-23 2025-01-23 DRMA HALE DAVID F Dir A - Grant — +78.7K 81.0K +3,553% —
DI 2025-01-23 2025-01-21 DRMA HALE DAVID F Dir A - Grant — +78.7K 78.7K New —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-01-23 A A 78,741 — 80,957 I By Hale BioPharma Ventures LLC — — (F2) The purchase price per share of Common Stock and accompanying Warrant was $1.27. (F4) Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
2 Derivative Warrant (Right to Buy) 2025-01-21 A A 78,741 — 78,741 I By Hale BioPharma Ventures LLC $1.27 · — to — 78,741 Common Stock (F2) The purchase price per share of Common Stock and accompanying Warrant was $1.27. (F4) Reporting person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. (F3) The Warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of Common Stock issuable upon exercise of the warrants. The Warrant will expire five years from the effective date of stockholder approval. The Warrant cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to such exercise, subject to certain exceptions.